Tebentafusp Continues to Demonstrate Benefit in Metastatic Uveal Melanoma
Source: Cancer Network, January 2024
Results from a long-term analysis of the phase 3 IMCgp100-202 trial indicate that tebentafusp results in better disease control and long-lasting responses in those with HLA-A*02:01–positive, previously untreated metastatic uveal melanoma.
Treatment with tebentafusp-tebn (Kimmtrak) yielded a long-lasting overall survival (OS) benefit in patients with HLA-A*02:01–positive, previously untreated metastatic uveal melanoma, according to data from a 3-year analysis of the phase 3 IMCgp100-202 trial (NCT03070392).
Investigators reported a median OS of 21.6 months (95% CI, 19.0-24.3) among patients treated with tebentafusp compared with 16.9 months (95% CI, 12.9-19.5) in the control arm (HR, 0.68; 95% CI, 0.54-0.87). Additionally, 72%, 45%, and 27% of patients were alive at 1 year, 2 years, and 3 years, respectively, in the tebentafusp group compared with 60%, 30%, and 18% in the control group.